Αρχική World News FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow... World News FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer Από Ogkologos - 6 Μαρτίου, 2025 675 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Improving cancer care for the LGBTQ+ community 26 Ιουλίου, 2021 Her Mother Died of Breast Cancer When She Was Five. 16... 25 Ιουνίου, 2019 FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer 15 Οκτωβρίου, 2024 Alcohol linked to more than 740,000 new cancer cases globally in... 14 Ιουλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... Lo que deben saber las personas con cáncer de mama y... Color-Blind Groom Sees Color For First Time After Bride Surprises Him... Summer Sun Safety Tips